EUVIMED · CrossrefJournal
Immunotherapy Advances
ISSN 2732-4303 · Oxford University Press (OUP)
Latest articles
The UK vaccine innovation pathway
Targeted 19F MRI for molecular imaging of the immune response and its theranostics
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure
Vaccination against tumour endothelial marker Robo4 inhibits tumour growth
The resilient subset: cancer stem cells at the core of immunotherapy resistance
Extracellular adenosine released by mesenchymal stromal cells from young hosts boosts the antimicrobial activity of neutrophils from aged hosts against Streptococcus pneumoniae
Optimized procurement of cancer-reactive T-cell receptors from clinical samples
NLRC5 expression within tumor cells is critical to activate adaptive and innate antitumor immune responses
Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting
Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer
Combination of proton-pump inhibitor and anti-CD3 F(ab’)2 for islet neogenesis and immune modulation in type 1 diabetes
Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials
Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
Human challenge models for vaccine development—strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report
Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma
Comparing DC subsets in solid tumors: what about DC3s?
Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
Turning the tide: harnessing vaccines and viruses to fight cancer
Harnessing natural killer cell effector function against cancer
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives
Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
Efficacy of smallpox vaccines against Mpox infections in humans
NLRP3 inflammasome activation in sensory neurons promotes chronic inflammatory and osteoarthritis pain
Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
Adrenergic signaling regulation of macrophage function: do we understand it yet?
EUVIMED